24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet)

Autor: Daniela Bertens, Tobias Hartmann, Christian Mychajliw, Niels Andreasen, Merja Hallikainen, Thomas Leyhe, Epameinondas Lyros, Johannes Schröder, Lutz Frölich, Noel Ellison, Ineke van Rossum, Yawu Liu, Hans Klünemann, Jennifer Kennel, Anneke M.J. van Hees, Gerwin Roks, Mara ten Kate, Klaus Fassbender, Lars-Olof Wahlund, Matthias Riemenschneider, Frederik Barkhof, Stephan Schiekofer, Alina Solomon, Marcus O. W. Grimm, Hilkka Soininen, Aline Klees-Rollmann, Seppo Helisalmi, Lucrezia Hausner, Miia Kivipelto, Stina Lindblom, Kaj Blennow, Johanna Ml Henselmans, Niklas Koehler, Dieter Lütjohann, Christoph Laske, Göran Hagman, Philip Scheltens, Tarja Lappalainen, Suzanne Hendrix, Yvonne Freund-Levi, Maxine Luley, Daniela Ramelli, Pieter Jelle Visser, Robert Schomburg, Teemu Paajanen, Nienke M.E. Scheltens, Ilona Hallikainen

Publikováno v: The Lancet Neurology, 16(12), 965-975. Lancet Publishing Group
The Lancet. Neurology
Lancet Neurology, 16(12), 965-975. Elsevier Science
Soininen, H, Solomon, A, Visser, P J, Hendrix, S B, Blennow, K, Kivipelto, M, Hartmann, T & LipiDiDiet clinical study group 2017, ' 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet) : a randomised, double-blind, controlled trial ', The Lancet Neurology, vol. 16, no. 12, pp. 965-975 . https://doi.org/10.1016/S1474-4422(17)30332-0

Background Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease dementia. LipiDiDiet investigated the effects of Fortasyn Connect on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f7f291b99a0117afc9dbe3f8653046
https://doi.org/10.1016/s1474-4422(17)30332-0

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

Autor: Philip Scheltens, Henrike Wolf, Daniela Bertens, R. C. Petersen, Ineke van Rossum, Pieter Jelle Visser, Patrick G. Kehoe, Flavio Nobili, Michael T. Heneka, José Luis Molinuevo, Alexandre de Mendonça, Stephanie J.B. Vos, Jacub Hort

Publikováno v: Alzheimer's Research & Therapy, 11(1):74. BioMed Central Ltd
Bertens, D, Vos, S, Kehoe, P, Wolf, H, Nobili, F, Mendonça, A, van Rossum, I, Hort, J, Molinuevo, J L, Heneka, M, Petersen, R, Scheltens, P & Visser, P J 2019, ' Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: A European survey ', Alzheimer's Research and Therapy, vol. 11, no. 1, 74 . https://doi.org/10.1186/s13195-019-0525-9
Alzheimer's Research and Therapy, 11(1):74. BioMed Central
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-12 (2019)
Bertens, D, Vos, S, Kehoe, P, Wolf, H, Nobili, F, Mendonça, A, van Rossum, I, Hort, J, Molinuevo, J L, Heneka, M, Petersen, R, Scheltens, P & Visser, P J 2019, ' Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care : a European survey ', Alzheimer's Research and Therapy, vol. 11, 74 (2019) . https://doi.org/10.1186/s13195-019-0525-9
Alzheimer's Research & Therapy
Alzheimer's research & therapy 11(1), 74 (2019). doi:10.1186/s13195-019-0525-9

Introduction The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3592acec515ede28100fd120bfdd23c
https://doi.org/10.1186/s13195-019-0525-9

Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects

Autor: Betty M, Tijms, Daniela, Bertens, Rosalinde E, Slot, Alida A, Gouw, Charlotte E, Teunissen, Philip, Scheltens, Wiesje M, van der Flier, Pieter Jelle, Visser

Publikováno v: Annals of neurology. 81(5)

We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid β1-42 (≥640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with fa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e6268606244868141c31cf5b7e3ffc1a
https://pubmed.ncbi.nlm.nih.gov/28318059

P4‐040: Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer's disease (AD) trials: An Alzheimer's disease neuroimaging initiative (ADNI) study

Autor: Betty M. Tijms, Pieter Jelle Visser, Philip Scheltens, Daniela Bertens

Publikováno v: Alzheimer's & Dementia. 11

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::152efb053f1a6d7e63863e8106c5b56b
https://doi.org/10.1016/j.jalz.2015.06.1744

Effect of helium on cerebral blood flow: A n=1 trial in a healthy young person

Autor: Daniela Bertens, Sanne M. Zinkstok, Jelle R. de Kruijk, Selma C. Tromp

Publikováno v: Perspectives in Medicine. 1(1-12):301-303

Summary Several experimental studies have shown that noble gases can have neuroprotective effects in cerebral ischemia. The exact mechanism is unknown; increased cerebral blood flow may play a role. In order to investigate this concept we performed a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950a1f42d0c75c4d464b30796e12cdd9